Guardant Health

Over the past few weeks, our Oncology and Screening teams came together for their annual National Sales Meetings — an incredible opportunity to align on strategy, sharpen skills, and celebrate 2024 achievements. With great energy and a shared focus, our teams are ready to embrace the new year and the opportunities ahead, driven by our mission to conquer cancer with data and a relentless commitment to patients. We’re proud to have such a dedicated team representing Guardant in the field. #ChallengeAccepted #OneGuardant

Today, we announced findings from our second annual “Closing the Gap: CRC Screening Insights” survey, conducted by The Harris Poll. ? The survey confirms that fear and anxiety about the #ColorectalCancer screening process could keep millions of Americans from getting screened — but it also highlights a promising solution. Both doctors and patients agree that having an FDA-approved blood test option, like Shield?, could help more people complete screening, which could potentially save more lives. Explore the full findings: https://lnkd.in/efJUnENT

Today, we reported our fourth quarter and full year 2024 financial results and provided an outlook for 2025.

We’re proud to be a sponsor of the 9th Annual Liquid Biopsy for Precision Oncology Summit next week in San Diego. Join our plenary session with Amar Das, MD, PhD, FACMI to learn how GuardantINFORM, our real-world data platform,?supports every phase of drug development. Plus, discover how Guardant Infinity's innovative methylation technology is shaping the future of precision oncology. Event details: https://lbx-summit.com

On International Day of Women and Girls in Science, we celebrate the incredible women who are breaking barriers, driving innovation, and inspiring the next generation of leaders in #Science and #STEM. Let’s recognize their impact and work towards a future where all women and girls have the opportunity to shine in these fields. #WomenInScience #WomenInSTEM

We’re proud to share that our Shield? blood test was recently featured on Health Uncensored with Dr. Drew! In the insightful segment, our VP of Clinical Development, Sam Asgarian, MD MBA, sat down with Dr. Drew to discuss the vital importance of early detection and how a more pleasant screening option can help. The segment also highlights John Gormly’s powerful story, showing how a routine screening with the Shield test led to an early diagnosis that changed his life. Watch the full segment: https://lnkd.in/gY5pGnHv

This #WorldCancerDay, we honor the global movement to unite against cancer and drive progress toward a healthier future. In the spirit of this day, we’re proud to share a powerful conversation between our co-CEO, Helmy Eltoukhy, and Forbes on the future of cancer detection and treatment. Their discussion explores how innovations in early detection and AI-driven insights have the potential to revolutionize patient care, improve outcomes, and bring us closer to a world where cancer is detected earlier and treated more effectively.

This #BlackHistoryMonth, we honor the trailblazers whose courage and perseverance have shaped history and continue to inspire future generations. Their work has rewritten history, defied boundaries, and ignited a movement of change that resonates to this day.

Today we announced an agreement with the Abu Dhabi Public Health Centre to introduce our Shield? blood test as part of a new #ColorectalCancer screening program, marking a significant step toward improving screening participation, early detection, and outcomes for UAE communities.

Today, we announced that we will present data showcasing the benefits of our precision oncology tools across cancer screening, recurrence monitoring, treatment selection, and therapy development at the American Society of Clinical Oncology (ASCO)'s #GI25. Data presentation details: https://lnkd.in/g6pU-q79